Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Retained Earnings (2017 - 2025)

Historic Retained Earnings for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$1.4 billion.

  • Arcus Biosciences' Retained Earnings fell 3285.16% to -$1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 billion, marking a year-over-year decrease of 3285.16%. This contributed to the annual value of -$1.1 billion for FY2024, which is 3333.33% down from last year.
  • Per Arcus Biosciences' latest filing, its Retained Earnings stood at -$1.4 billion for Q3 2025, which was down 3285.16% from -$1.2 billion recorded in Q2 2025.
  • Arcus Biosciences' 5-year Retained Earnings high stood at -$275.0 million for Q4 2021, and its period low was -$1.4 billion during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$697.0 million (2023), whereas its average is -$750.0 million.
  • Over the last 5 years, Arcus Biosciences' Retained Earnings had its largest YoY gain of 1620.55% in 2021, and its largest YoY loss of 10074.55% in 2021.
  • Over the past 5 years, Arcus Biosciences' Retained Earnings (Quarter) stood at -$275.0 million in 2021, then tumbled by 97.09% to -$542.0 million in 2022, then tumbled by 56.64% to -$849.0 million in 2023, then crashed by 33.33% to -$1.1 billion in 2024, then decreased by 21.82% to -$1.4 billion in 2025.
  • Its last three reported values are -$1.4 billion in Q3 2025, -$1.2 billion for Q2 2025, and -$1.2 billion during Q1 2025.